(MENAFN- PR Newswire) "With the integration of hfCas12Max, Vita Therapeutics can accelerate the development of their hypoimmunogenic cell therapies, paving the way for life-changing treatments to reach patients sooner," said Craig Christianson, CEO of Synthego. "Our goal is to make therapeutic CRISPR solutions more accessible by removing traditional bottlenecks with reduced upfront licensing fees and a lower total IP cost as the therapy advances."

Synthego and Vita partner to integrate hfCas12Max, with reduced IP costs to accelerate Vita's advanced CRISPR therapies.

Post thi

Synthego introduced the hfCas12Max CRISPR system in 2024 , the first in its portfolio of high-fidelity nucleases designed specifically for therapeutic applications. "With encouraging early performance data, Vita Therapeutics plans to leverage hfCas12Max to develop hypoimmunogenic master cell banks (MCBs), which will serve as a critical platform for advancing our iPSC-based therapies for neuromuscular disorders. We're excited about this partnership and the impact it can have on the patients we're hoping to treat," said Douglas Falk, CEO of Vita Therapeutics.

With the recent addition of eSpoT-ON , Synthego continues to elevate its high-fidelity nuclease portfolio, delivering new opportunities for therapeutic advancement.

About Synthego
Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models and exceptional technical expertise, Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies.

About Vita Therapeutics
‍ Vita Therapeutics is a biotechnology company developing state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases. Vita Therapeutics uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. The Company is progressing its lead program VTA-200 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) using its proprietary hypoimmunogenic cell line.

SOURCE Synthego

MENAFN08042025003732001241ID1109401451